SPRC Live signals | Maximize Profits with Getagraph.com

SELL 119833 min ago

@ $3.99

Issued: 6 Feb 2024 @ 09:45

Return: -64.41%

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 15:55):

Stats
Today's Volume	134 035
Average Volume	834 604
Market Cap	3.48M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00700 (0.49%)

Volume Correlation

Long: 0.09 (neutral)

Short: 0.21 (neutral)

Signal:(56.484) Neutral

SciSparc Ltd. Correlation

10 Most Positive Correlations
MXIM	0.937
HYMC	0.83
LSBK	0.801

10 Most Negative Correlations
IKNX	-0.851
APOP	-0.841
CMLF	-0.826
MAGS	-0.805
MOSY	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SciSparc Ltd. Correlation - Currency/Commodity

0.36
( neutral )

0.61
( weak )

0.00
( neutral )

-0.74
( moderate negative )

-0.50
( neutral )

SciSparc Ltd. Financials

Annual	2023
Revenue:	$2.88M
Gross Profit:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
Revenue:	$2.88M
Gross Profit:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
Revenue:	$1.35M
Gross Profit:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.